Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloid beta-Peptides | 5 | 2025 | 230 | 0.640 |
Why?
|
| Thrombocytopenia | 2 | 2005 | 205 | 0.400 |
Why?
|
| Memory, Episodic | 2 | 2023 | 52 | 0.390 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 569 | 0.300 |
Why?
|
| Pharmaceutical Services | 1 | 2008 | 87 | 0.270 |
Why?
|
| Valproic Acid | 1 | 2007 | 46 | 0.260 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2007 | 41 | 0.260 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 58 | 0.260 |
Why?
|
| Heparin | 2 | 2005 | 258 | 0.260 |
Why?
|
| Telomerase | 2 | 2010 | 246 | 0.250 |
Why?
|
| Education, Pharmacy | 1 | 2008 | 128 | 0.250 |
Why?
|
| Medical Records | 1 | 2007 | 182 | 0.250 |
Why?
|
| NAD | 2 | 2002 | 79 | 0.230 |
Why?
|
| Crystallins | 2 | 2002 | 61 | 0.220 |
Why?
|
| Temporal Lobe | 1 | 2025 | 102 | 0.220 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 57 | 0.220 |
Why?
|
| Thromboembolism | 1 | 2005 | 117 | 0.220 |
Why?
|
| Lens, Crystalline | 2 | 2002 | 131 | 0.210 |
Why?
|
| Frontal Lobe | 1 | 2025 | 160 | 0.210 |
Why?
|
| Anticoagulants | 2 | 2005 | 667 | 0.210 |
Why?
|
| Saliva | 1 | 2025 | 240 | 0.200 |
Why?
|
| Glutathione | 2 | 2002 | 357 | 0.200 |
Why?
|
| Community Participation | 1 | 2024 | 132 | 0.200 |
Why?
|
| Ultraviolet Rays | 2 | 2002 | 399 | 0.190 |
Why?
|
| Memory Disorders | 1 | 2023 | 176 | 0.190 |
Why?
|
| Memory | 1 | 2023 | 258 | 0.180 |
Why?
|
| Kynurenine | 1 | 2002 | 115 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2024 | 298 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 617 | 0.170 |
Why?
|
| Pediatrics | 1 | 2008 | 1075 | 0.160 |
Why?
|
| Fibroblasts | 1 | 2004 | 1001 | 0.150 |
Why?
|
| Positron-Emission Tomography | 3 | 2025 | 304 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 391 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 1094 | 0.130 |
Why?
|
| Brain | 2 | 2025 | 2786 | 0.120 |
Why?
|
| Aniline Compounds | 2 | 2025 | 104 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2012 | 29 | 0.100 |
Why?
|
| Nonprescription Drugs | 1 | 2012 | 64 | 0.090 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 57 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 204 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2002 | 557 | 0.080 |
Why?
|
| Humans | 15 | 2025 | 138429 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 122 | 0.070 |
Why?
|
| Overweight | 1 | 2012 | 571 | 0.070 |
Why?
|
| Aged | 5 | 2025 | 24078 | 0.070 |
Why?
|
| Phenobarbital | 1 | 2007 | 18 | 0.070 |
Why?
|
| Phenytoin | 1 | 2007 | 21 | 0.070 |
Why?
|
| Telomere | 1 | 2010 | 274 | 0.070 |
Why?
|
| Hyperammonemia | 1 | 2007 | 15 | 0.070 |
Why?
|
| Hallucinations | 1 | 2007 | 31 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 116 | 0.070 |
Why?
|
| Fructose | 1 | 2007 | 113 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 267 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 411 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2007 | 105 | 0.060 |
Why?
|
| Ethylene Glycols | 1 | 2025 | 16 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2025 | 18 | 0.060 |
Why?
|
| Pipecolic Acids | 1 | 2005 | 26 | 0.060 |
Why?
|
| Hirudins | 1 | 2005 | 52 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2007 | 214 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 527 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2010 | 788 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 786 | 0.060 |
Why?
|
| New Mexico | 1 | 2024 | 94 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 1029 | 0.050 |
Why?
|
| Clone Cells | 1 | 2004 | 265 | 0.050 |
Why?
|
| Arginine | 1 | 2005 | 260 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 1079 | 0.050 |
Why?
|
| RNA | 1 | 2010 | 924 | 0.050 |
Why?
|
| Seizures | 1 | 2007 | 430 | 0.050 |
Why?
|
| Antibodies | 1 | 2005 | 404 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 7664 | 0.050 |
Why?
|
| Entorhinal Cortex | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cell Death | 1 | 2004 | 375 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 794 | 0.050 |
Why?
|
| Orthopedic Procedures | 1 | 2005 | 228 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2004 | 190 | 0.050 |
Why?
|
| Acrylates | 1 | 2002 | 48 | 0.050 |
Why?
|
| Benzoates | 1 | 2002 | 46 | 0.050 |
Why?
|
| Middle Aged | 4 | 2025 | 33628 | 0.050 |
Why?
|
| Male | 6 | 2025 | 67994 | 0.050 |
Why?
|
| Glucosides | 1 | 2002 | 48 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1029 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 184 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 1355 | 0.050 |
Why?
|
| Female | 6 | 2025 | 73750 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2005 | 505 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2025 | 694 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 470 | 0.040 |
Why?
|
| Cell Survival | 1 | 2004 | 1126 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 898 | 0.040 |
Why?
|
| Kinetics | 1 | 2004 | 1648 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 179 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 1054 | 0.040 |
Why?
|
| Cattle | 1 | 2002 | 989 | 0.040 |
Why?
|
| Cell Line | 1 | 2004 | 2877 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 792 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1797 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2024 | 1732 | 0.030 |
Why?
|
| Hippocampus | 1 | 2022 | 928 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1472 | 0.030 |
Why?
|
| Cognition | 1 | 2023 | 1178 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 6838 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 4090 | 0.030 |
Why?
|
| Behind-the-Counter Drugs | 1 | 2012 | 1 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 25 | 0.020 |
Why?
|
| Laxatives | 1 | 2012 | 20 | 0.020 |
Why?
|
| Lactones | 1 | 2012 | 58 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2007 | 10879 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 21514 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2007 | 11128 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 38203 | 0.020 |
Why?
|
| Lung | 1 | 2004 | 4069 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 2010 | 5 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2010 | 68 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3634 | 0.020 |
Why?
|
| Retroviridae | 1 | 2010 | 103 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 136 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 232 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2007 | 15794 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 326 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 336 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 13311 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 983 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1229 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1758 | 0.020 |
Why?
|
| Child | 1 | 2007 | 21876 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2010 | 1318 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2479 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 4175 | 0.010 |
Why?
|
| Animals | 1 | 2002 | 37222 | 0.010 |
Why?
|
| United States | 1 | 2012 | 14963 | 0.010 |
Why?
|